Navigation Links
Prostate Cancer Test a Flop in Study
Date:5/3/2010

Doesn't distinguish aggressive tumors from slow-moving malignancies

MONDAY, May 3 (HealthDay News) -- A technique that urologists had hoped would make it possible to distinguish men with prostate cancer who need treatment from those who would only need watchful waiting didn't work well, researchers report.

The technique, called PSA kinetics, measures changes in the rate at which the prostate gland produces a protein called prostate-specific antigen. A significant increase in PSA kinetics, measured by the time during which PSA production doubles or increases at a rapid rate, is supposed to indicate the need for treatment, by radiation therapy or surgery.

PSA kinetics has long been used to measure the effectiveness of treatment. A number of cancer centers have started to use it as a possible method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be left alone.

Recent studies indicating that many men with slow-growing prostate cancers undergo unnecessary treatment have given urgency to the search for such a tool, especially considering that side effects of treatment can include incontinence and impotence.

But the study indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr. Ashley E. Ross, a urology resident at the Johns Hopkins University Brady Urological Institute, and lead author of a report on the technique published online May 3 in the Journal of Clinical Oncology.

The report describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer -- the kind that often doesn't require treatment -- for an average of 2.9 years. The results of PSA tests were compared with biopsies -- tissue samples -- that measured the progression of the cancers.

The trial is part of a study, under supervision of Dr. H. Ballentine Carter, d
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Reviews Side Effects From Prostate Cancer Therapy
2. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
3. FDA Approval of new Prostate Treatment Shows Promise of Cancer Immunotherapy
4. Prostate Cancer Vaccine Gains FDA Approval
5. Prostate Cancer Vaccine May Get FDA Approval
6. Prostate cancer: Risk increases with the number of affected family members
7. ASTRO president speaks on prostate cancer at MEDCAC meeting
8. Does the weather cause northerners to get more prostate cancer?
9. Weather Might Influence Prostate Cancer
10. Weight Gain, Smoking May Make Prostate Cancer Deadlier
11. Weight Gain, Smoking May Make Prostate Cancer More Deadly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... On March 5, 2015, Portland Trail Blazers ... the season with a torn Achilles tendon in his ... were competing against Dallas, and was confirmed via an ... M.D., who has treated many professional athletes, voiced his ... be prevented. , "Part of the problem regarding ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The ... the Patients’ Access to Treatments Act (PATA) that ... week by Reps. David B. McKinley (R-WV) and ... limit cost-sharing requirements for medications placed in a ... by reducing patients’ out-of-pocket expenses. , This legislation ...
(Date:3/26/2015)... 26, 2015 Volunteers will collectively walk ... Parkinson’s disease and funds to support the American ... Burden – Find the Cure. The Optimism ... place in more than 20 locations including, Boston, Chicago, ... San Antonio, Minnesota, Seattle, St. Louis, New York, Nevada, ...
(Date:3/26/2015)... 26, 2015 In preparation for the ... Revolution, founded by Samir Becic, has issued “report ... personal health and fitness, as well as their promotion ... list includes Sen. Ted Cruz, who has officially announced ... all other politicians who have shown interest in running ...
(Date:3/26/2015)... CRN International took the podium this ... celebrate the achievement of jobseekers from five statewide locations ... 500 people. , The program, called Platform to Employment ... partnership with the Connecticut Department of Labor, takes active ... and place them at appropriate companies. CRN, a 40-year-old ...
Breaking Medicine News(10 mins):Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act 2Health News:American Parkinson Disease Association 2015 Optimism Walk Season Launches Nationwide 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:CRN International Shows Support For Groundbreaking Connecticut Program To Aid The Unemployed 2
... can be significantly reduced by providing a simple intervention ... and alternatives of various imaging modalities, according to a ... Island, NY. , "Given the increased awareness ... medical imaging we hypothesized that a simple intervention of ...
... a strong relationship with their parents may start drinking at ... risk of developing alcohol problems, a new study suggests. , ... Journal of Studies on Alcohol and Drugs , underscore the ... , Past studies have suggested that the age at which ...
... A new study shows that the SAVI applicator, a ... partial breast irradiation, carries a low infection risk, a ... radiation oncologists and surgeons at the Moores UCSD Cancer ... indicates that other complications such as seromas, pockets ...
... (NYSE: VRX ) today announced that results ... clinical trial for taribavirin, a prodrug of ribavirin which ... C in conjunction with a pegylated interferon, was presented ... Liver (EASL) 44th Annual Meeting in Copenhagen, Denmark. ...
... at higher risk of aggressive recurrence only 8 months ... U.S. male military veterans exposed to the Agent Orange ... prostate cancer, a new study finds. , It included ... Of those, the 206 men who,d been exposed to ...
... NBTY, Inc. (NYSE: NTY ) ( www.NBTY.com ... supplements, today announced results for the fiscal second quarter and ... quarter ended March 31, 2009, net sales were $596 million ... March 31, 2008, an increase of $63 million or 12%. ...
Cached Medicine News:Health News:Good relationship with parents may prevent teen drinking problems 2Health News:Radiation device in the breast reduces complications for early stage breast cancer patients 2Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 2Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 3Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 4Health News:Agent Orange Exposure Tied to Prostate Cancer Return 2Health News:NBTY Reports Second Quarter Results 2Health News:NBTY Reports Second Quarter Results 3Health News:NBTY Reports Second Quarter Results 4Health News:NBTY Reports Second Quarter Results 5Health News:NBTY Reports Second Quarter Results 6Health News:NBTY Reports Second Quarter Results 7Health News:NBTY Reports Second Quarter Results 8Health News:NBTY Reports Second Quarter Results 9Health News:NBTY Reports Second Quarter Results 10Health News:NBTY Reports Second Quarter Results 11Health News:NBTY Reports Second Quarter Results 12Health News:NBTY Reports Second Quarter Results 13Health News:NBTY Reports Second Quarter Results 14Health News:NBTY Reports Second Quarter Results 15Health News:NBTY Reports Second Quarter Results 16Health News:NBTY Reports Second Quarter Results 17Health News:NBTY Reports Second Quarter Results 18Health News:NBTY Reports Second Quarter Results 19Health News:NBTY Reports Second Quarter Results 20
(Date:3/26/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today ... from the Israeli patent office with claims for administering ... damage caused by an increase in blood flow, as ... after a blockage causing a heart attack or in ... can be caused to the heart attack or stroke ...
(Date:3/26/2015)... March 26, 2015  Flexpoint Sensor Systems, Inc. (OTCBB: ... it has received and shipped during the last 90 ... of interest in the sensors for gloves and medical ... have had custom sensors built for them. Some of ... custom sensors for medical rehab; a major international electronics ...
(Date:3/26/2015)... VEGAS , March 26, 2015 ... sales agreement with Radlink, Inc., an emerging global ... real-time image guidance with its hip replacement systems. ... commitment to help improve patient outcomes, increase patient ... conjunction with the 81st annual meeting of the ...
Breaking Medicine Technology:RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Flexpoint Sensor Systems, Inc. Expands Customer Base with New Orders of Sensors 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3
... Mylan Inc. (Nasdaq: MYL ) today ... entered into a settlement agreement with Warner Chilcott resolving ... as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 ... mg (28-Day Regimen). This medication is an oral contraceptive. ...
... NEW YORK, Oct. 19, 2011 Reportlinker.com announces ... in its catalogue: Syncria ... 2020 http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Forecasts to 2020 Summary ...
Cached Medicine Technology:Mylan Announces Femcon® Fe Settlement Agreement 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Sodium in serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: